Business
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
RAHWAY, N.J., November 24, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/2231bd7d85d312ba78f817f960e54109"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jYevUVgsT4uuoF6DXUuDvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2231bd7d85d312ba78f817f960e54109","width":480,"height":217}},"lazy":false},{"type":"text","content":"First presentation for MK-1045, a novel CD19xCD3 T-cell engager in patients with certain types of leukemia and lymphoma, and for bomedemstat, an LSD1 inhibitor, in patients with polycythemia vera","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"New data demonstrate continued progress with nemtabrutinib, an investigational non-covalent BTK inhibitor","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., November 24, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates, with more than 20 abstracts being presented.","length":563,"tagName":"p"},{"type":"text","content":""The data we’re sharing at ASH 2025 reflect the continued growth and evolution of our promising hematology pipeline," said Dr. Gregory Lubiniecki, vice president, global clinical development, Merck Research Laboratories. "We continue to build on our leadership in oncology by advancing a diverse portfolio of investigational candidates and exploring novel modalities with the goal of improving outcomes and helping to address significant unmet needs for patients with hematologic neoplasms and malignancies."","length":528,"tagName":"p"},{"type":"text","content":"Data presentations will feature Merck’s pipeline candidates, including: MK-1045, an investigational CD19xCD3 T-cell engager; bomedemstat (MK-3543), an investigational, orally available lysine-specific demethylase 1 (LSD1) i...